Arrowhead said it has met both of these conditions in a July 28 release and now expects to receive the $100 million within 60 days. The company also said it plans on reaching the second enrollment ...

After months of searching for strategic options, Adaptimmune is offloading its cell therapies to a global pharma, which plans ...

MapLight Therapeutics has raised a $372.5 million series D round, clearing the biotech to chart a course through phase 2 for ...

Boehringer Ingelheim is continuing to explore its newfound enthusiasm for eye health, penning a $1 billion biobucks pact with ...

Decentralized Clinical Trials (DCTs) are transforming how we collect clinical data, but this evolution brings unprecedented challenges in data quality, complexity, and integration.

Atai Life Sciences’ schizophrenia drug has failed to improve cognition in a phase 2 study, leading the biotech to reaffirm ...

A phase 3 trial of Celcuity’s breast cancer combination has hit its primary endpoints, blasting past the biotech’s bar for ...

Having recently scored approval for Nucala in chronic obstructive pulmonary disease (COPD), GSK has now signed a major ...

Olympus has teamed up with Revival Healthcare Capital to launch a joint venture aimed at bringing robotics to gastrointestinal procedures.  | Swan EndoSurgical plans to develop a minimally invasive, ...

Roche has obtained European approval for a blood test to help rule out Alzheimer’s disease, allowing patients to avoid additional exams for the condition after showing signs of cognitive | According ...

Chinese biotech company Leads Biolabs has hit the Hong Kong stock exchange, snagging $189 million through an initial public offering on the HKEX. | Chinese biotech Leads Biolabs has hit the Hong Kong ...

Bristol Myers Squibb has raided AstraZeneca to find its next chief medical officer, persuading Cristian Massacesi, M.D., to ...